Background: Morning symptoms associated with COPD have a negative impact on patients' quality of life. Long-acting bronchodilators with rapid onset may relieve patients' symptoms. In the Symptoms and Pulmonary function in the moRnING study, we prospectively compared the rapid onset bronchodilator profile of glycopyrronium (GLY) and tiotropium (TIO) during the first few hours after dosing in patients with moderate-to-severe COPD.
Methods: Patients were randomized (1:1) to receive either once-daily GLY (50 μg) or TIO (18 μg) and corresponding placebos in a cross-over design for 28 days. The primary objective was to demonstrate the superiority of GLY versus TIO in area under the curve from 0 to 4 hours (AUC0-4h) forced expiratory volume in 1 second (FEV1) after the first dose. The secondary objective was to compare GLY versus TIO using the patient reported outcomes Morning COPD Symptoms Questionnaire 3 hours post-inhalation.
Results: One-hundred and twenty-six patients were randomized (male 70.2%; mean age 65.7 years) and 108 patients completed the study. On Day 1, GLY resulted in significantly higher FEV1 AUC0-4h after the first dose versus TIO (treatment difference [Δ], 0.030 L, 95% confidence interval 0.004-0.056, P=0.025). Improvements in morning COPD symptoms from baseline at Days 1 and 28 were similar between GLY and TIO. Post hoc analysis of the FEV1 AUC0-4h by time point on Day 1 showed significant improvements in patients receiving GLY versus TIO at 5 minutes (Δ=0.029 L, P=0.015), 15 minutes (Δ=0.033 L, P=0.026), and 1 hour (Δ=0.044 L, P=0.014). Safety results were comparable between both treatments.
Conclusion: The SPRING study demonstrates the superiority of GLY versus TIO in terms of superior bronchodilation in the first 4 hours after administration, thus extending the clinical data that support a faster onset of action of GLY versus TIO.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934556 | PMC |
| http://dx.doi.org/10.2147/COPD.S106127 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic factors for refractory outcome in localizing TIO: experience in a tertiary center.
J Clin Endocrinol Metab
January 2025
Division of Endocrinology and Metabolism, Department of Medicine, Mayo Clinic Rochester, USA.
Context: TIO, a paraneoplastic disorder characterised by renal phosphate wasting, is cured by surgical removal of the culprit tumour. Despite correct localization, some remain refractory to intervention, resulting in substantial long-term medical complications.
Aim: We aim to identify risk factors associated with a refractory outcome.
Comparative effectiveness of olodaterol/tiotropium and vilanterol/umeclidinium among COPD patients: a high-dimensional propensity score matched new user cohort study in a US medicare population.
Expert Rev Respir Med
December 2024
Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Background: Two long-acting muscarinic antagonist inhaler fixed dose combinations (olodaterol/tiotropium (OLO/TIO) and vilanterol/umeclidinium (VI/UMEC)) have once-a-day dosing for managing chronic obstructive pulmonary disease (COPD). This study aimed to compare clinical effectiveness of these inhalers in terms of ability to prevent severe COPD exacerbations in a United States Medicare population.
Research Design And Methods: Using nationally representative Medicare data (2013-2019), we employed a new user, active comparator design among beneficiaries aged 65 years and older with COPD.
Evaluation of comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of RCTs.
BMC Pulm Med
December 2024
Department of Respiratory and Critical Care Medicine, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, Henan, China.
Background: UMEC/VI administered via a combination inhaler is associated with a clinically significant improvement in lung function and health-related quality of life in patients with mild-to-moderate COPD. However, their efficacy compared to other bronchodilator mono or dual therapies still remains unclear.
Objective: The objective of this research was to evaluate the therapeutic efficacy of UMEC/VI dual and UMEC/VI/FF triple therapies versus alternative bronchodilator regimens in COPD patients.
Isolated Rhodium Atoms Activate Porous TiO for Enhanced Electrocatalytic Conversion of Nitrate to Ammonia.
Adv Sci (Weinh)
January 2025
National energy key laboratory for new hydrogen-ammonia energy technologies, Foshan Xianhu Laboratory, Foshan, 528200, P. R. China.
The direct electrochemical reduction of nitrate to ammonia is an efficient and environmentally friendly technology, however, developing electrocatalysts with high activity and selectivity remains a great challenge. Single-atom catalysts demonstrate unique properties and exceptional performance across a range of catalytic reactions, especially those that encompass multi-step processes. Herein, a straightforward and cost-effective approach is introduced for synthesizing single-atom dispersed Rh on porous TiO spheres (Rh-TiO), which functions as an efficient electrocatalyst for the electroreduction of NO to NH.
View Article and Find Full Text PDFPhotocatalytic degradation of microcystins from a field-collected cyanobacterial assemblage by 3D printed TiO structures using artificial versus solar irradiation.
J Environ Manage
December 2024
US Army Engineer Research and Development Center, Environmental Laboratory, Vicksburg, MS 39180, USA.
Article Synopsis
- Microcystins from freshwater cyanobacteria pose risks to human and ecological health, necessitating innovative treatment technologies like TiO photocatalysis.
- 3D Printing (3DP) allows for the immobilization of TiO, creating effective photocatalyst structures that can be adapted to different environments.
- In experiments, TiO embedded in 3DP polylactic acid (PLA) significantly reduced microcystin half-lives, demonstrating its potential for practical applications in various light conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!